Cognition Therapeutics
Cognition Therapeutics is a clinical-stage neuroscience company focused on developing oral medications to treat neurodegenerative disorders such as Alzheimer's disease and dementia with Lewy bodies. Their mission is to develop safe, effective, and easy-to-administer treatments that slow disease progression, with a lead product candidate, zervimesine (CT1812), designed to protect neurons by targeting cellular damage response mechanisms.
Industries
Nr. of Employees
small (1-50)
Cognition Therapeutics
Pittsburgh, Pennsylvania, United States, North America
Patents
Isoindoline compositions and methods for treating neurodegenerative disease
US-11691947-B2
View DetailsIsoindoline compositions and methods for treating neurodegenerative disease
US-10611728-B2
View DetailsIsoindoline compositions and methods for treating neurodegenerative disease
US-10207991-B2
View Details
Isoindoline compositions and methods for treating neurodegenerative disease
US-11691947-B2
View DetailsIsoindoline compositions and methods for treating neurodegenerative disease
US-10611728-B2
View DetailsIsoindoline compositions and methods for treating neurodegenerative disease
US-10207991-B2
View DetailsProducts
Lead clinical-stage oral small-molecule sigma-2 receptor modulator (clinical candidate)
Once-daily oral small-molecule investigational therapeutic that binds the sigma-2 receptor complex to modulate cellular damage response processes (e.g., autophagy, protein trafficking) and displace toxic protein oligomers; under clinical evaluation for Alzheimer’s disease and dementia with Lewy bodies.
Lead clinical-stage oral small-molecule sigma-2 receptor modulator (clinical candidate)
Once-daily oral small-molecule investigational therapeutic that binds the sigma-2 receptor complex to modulate cellular damage response processes (e.g., autophagy, protein trafficking) and displace toxic protein oligomers; under clinical evaluation for Alzheimer’s disease and dementia with Lewy bodies.
Services
Sponsor-led design and execution of multi-phase clinical trials (Phase 1–2) assessing safety, tolerability, pharmacodynamic biomarkers and exploratory efficacy in neurodegenerative diseases.
In-house and collaborative proteomic and transcriptomic analyses of CSF, plasma and preclinical tissue to identify pharmacodynamic biomarkers and molecular correlates of treatment.
Sponsor-led design and execution of multi-phase clinical trials (Phase 1–2) assessing safety, tolerability, pharmacodynamic biomarkers and exploratory efficacy in neurodegenerative diseases.
In-house and collaborative proteomic and transcriptomic analyses of CSF, plasma and preclinical tissue to identify pharmacodynamic biomarkers and molecular correlates of treatment.
Expertise Areas
- Clinical trial management
- Biomarker discovery and validation
- Small-molecule drug discovery
- CMC and process development
Key Technologies
- Sigma-2 receptor modulation
- CSF sampling with indwelling catheter
- Proteomics (CSF and plasma)
- Transcriptomics
News & Updates
A clinical trial study published in Alzheimer's & Dement (N Y) in 2019.
A poster presented at AD/PD 2025 in Vienna, Austria, detailing effects of CT1812 in Alzheimer’s disease.
A poster presented at SfN 2023 in Washington DC, exploring the role of sigma-2 receptor modulators in Alzheimer’s disease.
A poster presented at AD/PD 2024 in Lisbon, Portugal, showing CT1812’s effect on α-synuclein.
A poster presented at SfN 2023 in Washington DC, investigating sigma-2 receptor modulators.
A study published in Neurobiology of Disease in 2024, assessing CT1812’s impact on Aβ oligomers.
A clinical trial study published in Alzheimer's & Dement (N Y) in 2019.
A poster presented at AD/PD 2025 in Vienna, Austria, detailing effects of CT1812 in Alzheimer’s disease.
A poster presented at SfN 2023 in Washington DC, exploring the role of sigma-2 receptor modulators in Alzheimer’s disease.
A poster presented at AD/PD 2024 in Lisbon, Portugal, showing CT1812’s effect on α-synuclein.
A poster presented at SfN 2023 in Washington DC, investigating sigma-2 receptor modulators.
A study published in Neurobiology of Disease in 2024, assessing CT1812’s impact on Aβ oligomers.